Title: Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma
Authors: Annemans, Lieven ×
Caekelbergh, Karin
Roelandts, Rik
Boonen, Hugo
Leys, Christoph
Nikkels, Arjen E
Van den Haute, V
Van Quickenborne, L
Verhaeghe, Evelien
Leroy, Bernard #
Issue Date: Sep-2008
Publisher: John libbey eurotext ltd
Series Title: European journal of dermatology vol:18 issue:5 pages:539-546
Abstract: Clinical trials have shown that photodynamic therapy using methyl aminolevulinate (MAL-PDT) is an effective treatment for actinic keratosis (AK), and nodular and superficial basal cell carcinoma (nBCC and sBCC) unsuitable for other available therapies. Economic evaluation models have shown that it is a cost effective intervention as well. The objectives of this prospective, observational, one arm study were (i) to verify in a real-life practice study the results obtained in previous clinical trials with MAL-PDT in the treatment of AK, nBCC and sBCC; (ii) to calculate the real-life cost of treatment and validate predictions from an economic evaluation model. Patients with AK and/or BCC were selected according to Belgian reimbursement criteria for treatment with MAL-PDT. Clinical response, cosmetic outcome and tolerability were assessed. MAL-PDT cost was calculated and compared to published model cost data. Data were collected from 247 patients (117 AK, 130 BCQ. A complete clinical response was obtained for 83% of AK (85/102) and BCC (97/116) patients. A good or excellent cosmetic outcome was obtained for 95% of AK patients and 93% of BCC patients. Tolerability was good: only 2 patients withdrew for adverse events. Clinical results were similar to previous studies. Total cost of care per patient was (sic)381 forAK, (sic)318 for nBCC, and (sic)298 for sBCC. Total cost per lesion was (sic)58 for AK (identical to model prediction), (sic)316 for nBCC and (sic)178 for sBCC (both within 20% of model prediction). The clinical results of MAL-PDT in this real-life practice study confirm those demonstrated in previous clinical trials. Costs calculated from this study confirm predicted cost-effectiveness in the original model for MAL-PDT in the management of AK and BCC.
ISSN: 1167-1122
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Dermatology
Laboratory of Dermatoimmunology (+)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science